DexCom (DXCM) PT Lowered to $90 at BMO Capital Following 2Q on 'Near-Term Medicare Reimbursement Disruption'
Tweet Send to a Friend
BMO Capital lowered its price target on DexCom (NASDAQ: DXCM) to $90.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
